JP2014500722A5 - - Google Patents

Download PDF

Info

Publication number
JP2014500722A5
JP2014500722A5 JP2013538823A JP2013538823A JP2014500722A5 JP 2014500722 A5 JP2014500722 A5 JP 2014500722A5 JP 2013538823 A JP2013538823 A JP 2013538823A JP 2013538823 A JP2013538823 A JP 2013538823A JP 2014500722 A5 JP2014500722 A5 JP 2014500722A5
Authority
JP
Japan
Prior art keywords
glucocerebrosidase
mutant recombinant
glucocerebrosidase protein
recombinant
protein according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014500722A (ja
JP6073796B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/059731 external-priority patent/WO2012064709A2/en
Publication of JP2014500722A publication Critical patent/JP2014500722A/ja
Publication of JP2014500722A5 publication Critical patent/JP2014500722A5/ja
Application granted granted Critical
Publication of JP6073796B2 publication Critical patent/JP6073796B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013538823A 2010-11-08 2011-11-08 増加した安定性および増加した保持触媒活性を有する変異型組換えβ−グルコセレブロシダーゼタンパク質 Active JP6073796B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41133110P 2010-11-08 2010-11-08
US61/411,331 2010-11-08
US41218010P 2010-11-10 2010-11-10
US61/412,180 2010-11-10
PCT/US2011/059731 WO2012064709A2 (en) 2010-11-08 2011-11-08 Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017000301A Division JP6457559B2 (ja) 2010-11-08 2017-01-05 増加した安定性および増加した保持触媒活性を有する変異型組換えβ−グルコセレブロシダーゼタンパク質

Publications (3)

Publication Number Publication Date
JP2014500722A JP2014500722A (ja) 2014-01-16
JP2014500722A5 true JP2014500722A5 (enExample) 2014-12-25
JP6073796B2 JP6073796B2 (ja) 2017-02-01

Family

ID=46051505

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013538823A Active JP6073796B2 (ja) 2010-11-08 2011-11-08 増加した安定性および増加した保持触媒活性を有する変異型組換えβ−グルコセレブロシダーゼタンパク質
JP2017000301A Active JP6457559B2 (ja) 2010-11-08 2017-01-05 増加した安定性および増加した保持触媒活性を有する変異型組換えβ−グルコセレブロシダーゼタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017000301A Active JP6457559B2 (ja) 2010-11-08 2017-01-05 増加した安定性および増加した保持触媒活性を有する変異型組換えβ−グルコセレブロシダーゼタンパク質

Country Status (19)

Country Link
US (4) US8962564B2 (enExample)
EP (2) EP2638152B1 (enExample)
JP (2) JP6073796B2 (enExample)
KR (1) KR101901467B1 (enExample)
CN (2) CN103314105B (enExample)
BR (1) BR112013011152A2 (enExample)
CA (1) CA2817011C (enExample)
CY (1) CY1118843T1 (enExample)
DK (1) DK2638152T3 (enExample)
ES (2) ES2743825T3 (enExample)
HR (1) HRP20161560T1 (enExample)
HU (1) HUE030932T2 (enExample)
LT (1) LT2638152T (enExample)
PL (1) PL2638152T3 (enExample)
PT (1) PT2638152T (enExample)
RS (1) RS55405B1 (enExample)
SI (1) SI2638152T1 (enExample)
SM (1) SMT201600431B (enExample)
WO (1) WO2012064709A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220125892A1 (en) * 2019-02-01 2022-04-28 OXYRANE UK Ltd. Glucocerebrosidase polypeptides
FI3850089T3 (fi) 2019-02-04 2024-02-14 Freeline Therapeutics Ltd Polynukleotidejä
JP2022547297A (ja) 2019-09-09 2022-11-11 エフ.ホフマン-ラ ロシュ アーゲー グルコセレブロシダーゼ変異体
US20230132790A1 (en) * 2020-03-29 2023-05-04 Yeda Research And Development Co. Ltd. Variants of beta-glucocerebrosidase for use in treating gaucher disease
CA3189801A1 (en) * 2020-07-29 2022-02-03 Freeline Therapeutics Limited Polypeptide
WO2023145814A1 (ja) * 2022-01-31 2023-08-03 株式会社日本触媒 向上した酵素活性または向上した安定性を有する組換えグルコセレブロシダーゼタンパク質
JPWO2023145813A1 (enExample) * 2022-01-31 2023-08-03
US20250145978A1 (en) * 2022-01-31 2025-05-08 Nippon Shokubai Co., Ltd. Glycosylated protein having glucocerebrosidase activity
EP4508206A1 (en) 2022-04-12 2025-02-19 F. Hoffmann-La Roche AG Fusion proteins targeted to the central nervous system
CN118715316B (zh) * 2022-10-08 2025-09-19 凌意(杭州)生物科技有限公司 用于治疗GCase缺乏相关疾病的多核苷酸
WO2025122912A1 (en) * 2023-12-08 2025-06-12 Denali Therapeutics Inc. Modified glucocerebrosidase polypeptides and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03503721A (ja) * 1988-12-23 1991-08-22 ジェンザイム コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
DE68926569T2 (de) 1988-12-23 1996-09-26 Genzyme Corp Cho-zellen befähigt enzymatisch aktive rekombinante-glukocerebrosidase zu produzieren
EP0979311A1 (en) 1997-04-30 2000-02-16 Of The University Of Minnesota Regents $i(IN VIVO) USE OF RECOMBINAGENIC OLIGONUCLEOBASES TO CORRECT GENETIC LESIONS IN HEPATOCYTES
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
EP1027069B1 (en) * 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
IL141403A0 (en) * 1998-08-28 2002-03-10 Univ Duke Deleted adenoviruses and methods of making and administering the same
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
IL150314A0 (en) * 1999-12-30 2002-12-01 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
AU2001253181A1 (en) * 2000-04-06 2001-10-23 Exegenics, Inc. Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase)
WO2002002597A2 (en) 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
EP1613264A4 (en) * 2003-04-16 2007-08-15 Yeda Res & Dev MEDICAMENT FOR THE TREATMENT OF GAUCHER DISEASE AND METHOD FOR IDENTIFYING IT
US20050265988A1 (en) 2004-03-18 2005-12-01 Byung-Kwon Choi Glycosylated glucocerebrosidase expression in fungal hosts
WO2008134628A2 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
KR20100017879A (ko) * 2007-05-22 2010-02-16 아미쿠스 세라퓨틱스, 인코포레이티드 이소파고민과 이의 유도체를 제조하는 새로운 방법
US20090148887A1 (en) 2007-11-02 2009-06-11 The Scripps Research Institute Genetically encoded boronate amino acid
BRPI0819092A2 (pt) 2007-11-02 2014-10-14 Scripps Research Inst Evolução direcionada usando proteínas que compreendem aminoácidos não naturais.

Similar Documents

Publication Publication Date Title
JP2014500722A5 (enExample)
WO2012064709A3 (en) Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
NL300874I2 (nl) Elosulfase alfa
WO2016138534A3 (en) Antisense-induced exon2 inclusion in acid alpha-glucosidase
JP2013519365A5 (enExample)
JP2011528896A5 (enExample)
NZ702801A (en) Treatment of sanfilippo syndrome type b
JP2012532596A5 (enExample)
JP2013520405A5 (enExample)
PH12016501439A1 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
CY1118934T1 (el) Παρασκευη ενεργης ακρως φωσφορυλιωμενης ανθρωπινης ν-ακετυλογαλακτοζαμινης-6-σουλφατασης και χρησεις αυτης
JP2014513952A5 (enExample)
MX2013001749A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
JP2010512795A5 (enExample)
WO2012000103A8 (en) Methods of targeting pten mutant diseases and compositions therefor
JP2013231081A5 (enExample)
JP2011037901A5 (enExample)
JP2021505620A5 (enExample)
JP2014518641A5 (enExample)
RU2017143580A (ru) Улучшенные последовательности уриказы и способы лечения
JP2013503110A5 (enExample)
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
JP2014513123A5 (enExample)
MX2022009874A (es) Inhibidores heterociclicos de peptidil arginina desiminasa 4 (pad4).
JP2012521366A5 (enExample)